Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049608 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00049608 is a Phase 1 study that was terminated before completion, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 51 participants.
The verdict
NCT00049608, a Phase 1 study, was terminated before completion, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Mistletoe may slow the growth of tumor cells and may be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine with mistletoe in treating patients who have advanced solid tumors.
Interventions
- DRUG gemcitabine hydrochloride
- DIETARY_SUPPLEMENT mistletoe extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2002-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049608
The ClinicalTrials.gov registry entry for NCT00049608 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00049608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049608 about?
NCT00049608 is a clinical study titled "Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Mistletoe may slow the growth of tumor cells and may be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of combini...
What is the current status of trial NCT00049608?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2002-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00049608?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), mistletoe extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00049608?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.